{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T21:53:48Z","timestamp":1649022828739},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1157\/13088589","type":"journal-article","created":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T09:35:57Z","timestamp":1149586557000},"page":"281-283","source":"Crossref","is-referenced-by-count":2,"title":["Trombosis venosa profunda: nuevos f\u00e1rmacos y futuras perspectivas terap\u00e9uticas"],"prefix":"10.1016","volume":"206","author":[{"given":"R.","family":"Garc\u00eda Vidal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Berga Fauria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.M.","family":"Paredero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1157\/13088589_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/0897190004271777","article-title":"The future of anticoagulation","volume":"5","author":"Dobesh","year":"2004","journal-title":"J Pharm Practice"},{"key":"10.1157\/13088589_bib2","doi-asserted-by":"crossref","first-page":"265S","DOI":"10.1378\/chest.126.3_suppl.265S","article-title":"The seventh ACCP conference on antithrombotic and thrombolytic therapy. New anticoagulant drugs","volume":"126","author":"Weitz","year":"2004","journal-title":"Chest"},{"key":"10.1157\/13088589_bib3","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised doubleblind comparison","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1157\/13088589_bib4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hipreplacement surgery: a randomised double-blind trial","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1157\/13088589_bib5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1001\/archinte.163.11.1337","article-title":"PENTasaccharide in Hip-FRA-ture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study","volume":"163","author":"Eriksson","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1157\/13088589_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa035451","article-title":"Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism","volume":"349","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1157\/13088589_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0049-3848(00)00399-6","article-title":"The direct thrombin inhibitor melagatran and its oral prodrug H 376\/95: intestinal absorption properties, biochemical and pharmacodynamic effects","volume":"101","author":"Gustafsson","year":"2001","journal-title":"Thromb Res"},{"key":"10.1157\/13088589_bib8","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S0140-6736(02)11469-3","article-title":"Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial","volume":"360","author":"Eriksson","year":"2002","journal-title":"Lancet"},{"key":"10.1157\/13088589_bib9","first-page":"299","article-title":"The oral direct thrombin inhibitor ximelagatran, and its subcutaneous form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism in total hip or total knee replacement: the EXPRESS study [abstract]","volume":"100","author":"Eriksson","year":"2002","journal-title":"Blood"},{"key":"10.1157\/13088589_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1538-7836.2003.00034.x","article-title":"A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I","volume":"1","author":"Eriksson","year":"2003","journal-title":"J Thromb Haemost"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256506727989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014256506727989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T22:50:00Z","timestamp":1547592600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014256506727989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0014256506727989"],"URL":"https:\/\/doi.org\/10.1157\/13088589","relation":{},"ISSN":["0014-2565"],"issn-type":[{"value":"0014-2565","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}